HEMATOLOGICAL DISEASES BIOSPECIMENS
Hematological Disease Biospecimens
Accelerate your blood disorder research with premium-quality biospecimens and rich genomic annotation
From confirmed diagnoses of Sickle Cell Disease and Amyloidosis to Essential Thrombocythemia and rare hemoglobin disorders, access the biospecimens and clinical data you need for breakthrough hematological research.
Access a Comprehensive Portfolio of Hematological Disease Biospecimens
Our donor network across the United States supports research into major blood disorders including Sickle Cell Disease, Amyloidosis, Essential Thrombocythemia, G6PD Deficiency, and rare hemoglobin variants. Whether you need cross-sectional or longitudinal collections, matched sample sets, or custom cohorts, we provide the precise specimens and deep genomic annotation required for transformative hematological research from study design to receipt of samples.
Understanding the natural history of blood disorders demands high-quality biospecimens collected from patients with confirmed diagnoses. Our direct-access model ensures you receive well characterized samples with comprehensive clinical documentation, enabling you to investigate disease mechanisms, validate biomarkers, and develop next-generation therapies for conditions that disproportionately affect underserved populations
Why Choose SanguineBio for Hematological Disease Specimen Solutions
Hematological disease research demands high-quality biospecimens, rigorous genomic annotation, and compliance with ethical standards.
Direct-to-Patient Model & Engaged Network
Our network across the United States allows access to well-characterized donors with confirmed hematological disease diagnoses, streamlining procurement so you can focus on discovery.
Custom collection services
If what you need isn't available in our inventory, we will recruit and collect from a custom cohort tailored to your specific inclusion/exclusion criteria, from study design to receipt of samples.
Access to Hard-to-Find Populations
Rare genotypes (HbSC, HbS-beta thalassemia), treatment-naïve versus treated patients, early versus advanced disease stages—we work with you to source the right patients for your research objectives.
Matched Sample Sets
Get multiple sample types from the same patient (e.g., whole blood, plasma, PBMCs, serum) for comprehensive biomarker analysis and multi-omics investigations
Comprehensive Genomic Annotation
Receive samples paired with rich patient data—demographics, confirmed disease diagnosis, genetic variants, treatment history, laboratory values, and natural history documentation when available.
Ethical Sourcing & Regulatory Compliance
Our processes meet high ethical and data-security standards (ISO certifications, HIPAA compliance) which gives you confidence in your research tools.
Hematological Disease Specimen Portfolio
Available Specimen Types Include:
Whole Blood
EDTA, heparin, or custom
anticoagulants
Plasma & Serum
with or without protease inhibitors
Peripheral Blood Mononuclear
Cells (PBMCs)
cryopreserved or viable
Isolated Cell Populations
B cells, T cells, NK cells
Bone Marrow Aspirates
when clinically indicated
Longitudinal Collections
to track natural history, treatment
response, and biomarker evolution
Rich Clinical and Molecular Annotation
Many of our infectious disease biospecimens come with detailed patient documentation, enabling them to function as true translational research tools.
Demographics & clinical characteristics
Confirmed disease diagnosis with specific genotype (e.g., HbSS, HbSC, JAK2 V617F, CALR mutations), age at diagnosis, gender,
race/ethnicity, family history, comorbidities, disease severity staging Recent studies demonstrate that specific genotypes correlate strongly with clinical
phenotype in Essential Thrombocythemia, with JAK2 V617F-positive patients showing distinct thrombotic risk profiles compared to CALR-mutated cases.1
Treatment history
Medication exposures (hydroxyurea, voxelotor, crizanlizumab, cytoreductive agents), transfusion history, gene therapy status, stem cell transplantation, chelation therapy
Molecular profiling
Where available, data may include biomarker levels, genetic or genomic data, gene expression profiles, metabolomics data, proteomic analysis, epigenetic markers
Natural History Data
Vaso-occlusive crisis frequency, hemolytic episodes, organ complications, transfusion
requirements, treatment response metrics, longitudinal laboratory trends
Ethical Sourcing and Regulatory Compliance
Trust and compliance are fundamental to our operations.
Ethical standards:
- Institutional Review Board (IRB)-approved patient consent documentation
- Patients engaged through transparent, compliant recruitment and consent processes
- All samples from confirmed diagnoses—never suspected cases
Regulatory & Data Security
- De-identified patient data in HIPAA-compliant format
- Certified quality management systems including ISO 9001, ISO 27001, ISO 27701 for information security and privacy3
- Full chain-of-custody documentation from collection to delivery
From Discovery to Therapy—Powering Every Step of Hematological Research
Whether you're exploring disease pathogenesis, developing diagnostics, or validating therapeutic strategies, our biospecimens support research across the hematological disease continuum:
Basic research
Investigate mechanisms of hemoglobin polymerization, clonal hematopoiesis, platelet dysfunction, oxidative stress pathways, and protein misfolding in amyloidosis
Understanding the molecular basis of HbS polymerization and vaso-occlusion has been fundamental to developing targeted therapies, with recent CRISPR-based approaches demonstrating curative potential through BCL11A disruption to reactivate fetal hemoglobin.4
Biomarker discovery & validation
Use longitudinal sets and matched controls to identify prognostic markers (NT-proBNP in cardiac amyloidosis, plasma-free heme in SCD, P-selectin in thrombosis)
More than 100 blood and urine biomarkers have been characterized in sickle cell disease, with markers of hemolysis, inflammation, and endothelial dysfunction providing complementary insights into disease activity and complication risk.5
Therapeutic development
Support drug discovery and clinical validation with well-characterized patient samples, treatment-naïve and treated cohorts, and monitoring of therapeutic response
Precision Medicine
Leverage genomic profiling in samples linked to phenotypic data and outcomes to enable precision medicine approaches for genotype-specific interventions
Diagnostics development
Develop and validate assays for early detection, prognostic stratification, or monitoring of Sickle Cell Disease, Amyloidosis, Essential Thrombocythemia, and other blood disorders.
Specialized Collections for Key Hematological Diseases
SICKLE CELL DISEASE & SICKLE CELL TRAIT
Access samples from patients with confirmed Sickle Cell Disease (HbSS, HbSC, HbS-beta thalassemia) across disease severity spectrum, as well as Sickle Cell Trait carriers (HbAS) for comparative studies. Available with comprehensive genotyping, hemoglobin electrophoresis data, vaso-occlusive crisis history, and transfusion records.
- Vaso-occlusive crisis mechanisms and biomarker development
- Gene therapy efficacy and safety monitoring
- Hydroxyurea response prediction
- Pain management and quality of life studies
- Health disparities research in African American and Hispanic populations6
Ready to Advance Your Respiratory & Metabolic Disease Research?
Our patient network across the United States supports comprehensive research into respiratory and metabolic conditions. Whether you need cross-sectional or longitudinal collections, matched sample sets, or custom cohorts, we provide the precise specimens and comprehensive genomic annotation required for breakthrough research.